A
Angelo Schenone
Researcher at University of Genoa
Publications - 253
Citations - 7064
Angelo Schenone is an academic researcher from University of Genoa. The author has contributed to research in topics: Medicine & Polyneuropathy. The author has an hindex of 40, co-authored 225 publications receiving 6063 citations.
Papers
More filters
Journal ArticleDOI
Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2
Alessandra Bolino,Maria Muglia,Francesca Luisa Conforti,Eric LeGuern,Mustafa A. Salih,Domna Maria Georgiou,Kyproula Christodoulou,Irena Hausmanowa-Petrusewicz,Paola Mandich,Angelo Schenone,Antonio Gambardella,F. Bono,Aldo Quattrone,Marcella Devoto,Anthony P. Monaco +14 more
TL;DR: Using a positional-cloning strategy, mutations occurring in the gene MTMR2, encoding myotubularin-related protein-2, a dual specificity phosphatase (DSP) are identified in unrelated CMT4B patients.
Journal ArticleDOI
Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease
TL;DR: The data indicate that an exquisitely tight control of mitochondrial dynamics, regulated by GDAP1, is crucial for the proper function of myelinated peripheral nerves.
Journal ArticleDOI
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
Guido Cavaletti,David R. Cornblath,Ingemar S. J. Merkies,Tjeerd J. Postma,Emanuela Rossi,Barbara Frigeni,Paola Alberti,Jordi Bruna,Roser Velasco,Andreas A. Argyriou,Haralabos P. Kalofonos,Dimitri Psimaras,Damien Ricard,Andrea Pace,Edvina Galiè,Chiara Briani,C. Dalla Torre,Catharina G. Faber,Roy I. Lalisang,W. Boogerd,W. Boogerd,Dieta Brandsma,Susanne Koeppen,Jörg Hense,Dawn J Storey,S. Kerrigan,Angelo Schenone,Sabrina Fabbri,Maria Grazia Valsecchi,Anna Mazzeo,Antonio Toscano,Brigitte A. Brouwer,B. Piras,C. Dominguez gonzalez,Chiara Tomasello,D. Binda,D. Cortinovis,E. Lindeck pozza,Els K. Vanhoutte,Francesca Lanzani,Francesca Pastorelli,Giuseppe Altavilla,Giuseppe Granata,I. Ghignotti,J. Heimans,Laura Mattavelli,Luca Padua,L. Reni,Mayienne Bakkers,Marta Campagnolo,M.E. Cazzaniga,M. Eurelings,Massimo Leandri,Marta Lucchetta,M. Penas prado,M. Russo,M Piatti,P. Bidoli,Robin Grant,R. Plasmati,R. J. Meijer,Susan G. Dorsey,Stefania Galimberti,Wolfgang Grisold,A. Pessino +64 more
TL;DR: Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN and future studies are planned to investigate the responsiveness aspects of these measures.
Journal ArticleDOI
Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
Davide Pareyson,Mary M. Reilly,Angelo Schenone,Gian Maria Fabrizi,Tiziana Cavallaro,Lucio Santoro,Giuseppe Vita,Aldo Quattrone,Aldo Quattrone,Luca Padua,Franco Gemignani,Francesco Visioli,Francesco Visioli,Matilde Laura,Davide Radice,Daniela Calabrese,Richard A. C. Hughes,Alessandra Solari +17 more
TL;DR: Ascorbic acid supplementation had no significant effect on neuropathy compared with placebo after 2 years, suggesting that no evidence is available to support treatment with ascorbIC acid in adults with CMT1A.
Journal ArticleDOI
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
Ivo N. van Schaik,Vera Bril,Nan van Geloven,Hans-Peter Hartung,Richard A. Lewis,Gen Sobue,John-Philip Lawo,Michaela Praus,Orell Mielke,Billie L. Durn,David R. Cornblath,Ingemar S. J. Merkies,A. Sabet,K. George,Leslie Roberts,R. Carne,Stefan Blum,Robert D. Henderson,P. Van Damme,J. Demeestere,S. Larue,C. D'Amour,Vera Bril,Ari Breiner,P. Kunc,Martin Vališ,J. Sussova,T. Kalous,R. Talab,M. Bednar,Toomas Toomsoo,Inna Rubanovits,Katrin Gross-Paju,U. Sorro,M. Saarela,Mari Auranen,Jean Pouget,Shahram Attarian,G. Le Masson,Anne-Cécile Wielanek-Bachelet,Claude Desnuelle,Emilien Delmont,Pierre Clavelou,D. Aufauvre,Jens Ejbye Schmidt,J. Zschuentssch,Claudia Sommer,D. Kramer,Olaf Hoffmann,C. Goerlitz,J. Haas,M. Chatzopoulos,R. Yoon,R. Gold,P. Berlit,A. Jaspert-Grehl,D. Liebetanz,A. Kutschenko,Martin Stangel,C. Trebst,P. Baum,Florian Then Bergh,Juliane Klehmet,Andreas Meisel,Fabian Klostermann,J. Oechtering,Helmar C. Lehmann,Michael Schroeter,Tim Hagenacker,D. Mueller,Anne D. Sperfeld,F. Bethke,Vivian E. Drory,A. Algom,David Yarnitsky,B. Murinson,A. Di Muzio,F. Ciccocioppo,Sandro Sorbi,Sabrina Matà,Angelo Schenone,Marina Grandis,Giuseppe Lauria,Daniele Cazzato,Giovanni Antonini,Stefania Morino,Dario Cocito,M. Zibetti,Takanori Yokota,Takuya Ohkubo,Takashi Kanda,M. Kawai,Kenichi Kaida,H. Onoue,Satoshi Kuwabara,Masahiro Mori,Masahiro Iijima,K. Ohyama,Masayuki Baba,M. Tomiyama,K. Nishiyama,Tsugio Akutsu,Kazumasa Yokoyama,K. Kanai,I. N. van Schaik,Filip Eftimov,Nicolette C. Notermans,Nora A. Visser,C. G. Faber,Janneke G. J. Hoeijmakers,Konrad Rejdak,U. Chyrchel-Paszkiewicz,C. Casanovas Pons,M. Alberti Aguiló,Josep Gamez,Maria Salvado Figueras,C. Marquez Infante,S. Benitez Rivero,Michael P. Lunn,Jasper M. Morrow,David Gosal,T. Lavin,I. Melamed,Alessandro Testori,Senda Ajroud-Driss,Daniela M. Menichella,Ericka Simpson,E. Chi-Ho Lai,Mazen M. Dimachkie,Richard J. Barohn,Said R. Beydoun,H. Johl,Dale J. Lange,Alexander Shtilbans,S. Muley,Shafeeq Ladha,Miriam Freimer,John T. Kissel,Norman Latov,Russell L. Chin,Eroboghene E. Ubogu,S. Mumfrey,T. Rao,P. MacDonald,Khema Sharma,Ginna Gonzalez,Jeffrey A. Allen,David Walk,Lisa D. Hobson-Webb,Karissa L. Gable +149 more
TL;DR: This study, which is to the authors' knowledge, the largest trial of CIDP to date and the first to study two administrations of immunoglobulins and two doses, showed that both doses of SCIg IgPro20 were efficacious and well tolerated, suggesting thatSCIg can be used as a maintenance treatment for C IDP.